Table 1

Baseline characteristics of the modified intention-to-treat population

Treatment groupTotal (N = 213)
Imeglimin 1,000 mg (n = 106)Placebo (n = 107)
Sex
 Female17 (16.0)29 (27.1)46 (21.6)
 Male89 (84.0)78 (72.9)167 (78.4)
Age (years)62.2 (9.61)61.9 (10.17)62.0 (9.87)
Age-group (years)
 <6554 (50.9)59 (55.1)113 (53.1)
 ≥6552 (49.1)48 (44.9)100 (46.9)
HbA1c (%)7.99 (0.764)7.93 (0.682)7.96 (0.723)
HbA1c (mmol/mol)64 (8.4)63 (7.5)63 (7.9)
Diabetes duration (years)7.70 (5.59)7.28 (6.15)7.49 (5.87)
Previous diabetes therapy
 Treatment naive76 (71.7)77 (72.0)153 (71.8)
 SGLT2-I4 (3.8)4 (3.7)8 (3.8)
 Another oral hypoglycemic agent26 (24.5)26 (24.3)52 (24.4)
Body weight (kg)70.98 (14.12)69.29 (12.85)70.13 (13.49)
BMI (kg/m2)25.66 (4.22)25.31 (4.12)25.49 (4.16)
eGFR (MDRD; mL/min/1.73 m2)72.49 (13.20)70.14 (11.79)71.31 (12.54)
CKD stage
 112 (11.3)7 (6.5)19 (8.9)
 273 (68.9)82 (76.6)155 (72.8)
 321 (19.8)18 (16.8)39 (18.3)
  • Data are reported as mean (SD) or n (%).